Blood test may guide chemo decisions for colorectal cancer patients

NCT ID NCT07562711

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is for people with high-risk stage II colorectal cancer who have a positive blood test for tumor DNA one month after surgery. It tests whether using that blood test to choose stronger or different chemotherapy can help clear the tumor DNA and prevent the cancer from coming back. About 340 participants will be randomly assigned to standard chemo or a personalized plan based on their blood test results.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Capecitabine, FOLFOX, CAPOX, FOLFIRI
What this could lead to: If successful, this could show that using a blood test to personalize chemotherapy after surgery reduces the chance of cancer returning in high-risk stage II colorectal cancer patients.
What could go wrong: This is a Phase 2 trial with 340 participants, so results are still early. The approach may not improve survival or could lead to unnecessary side effects from stronger chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY COLORECTAL CANCER CTDNA

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.